| Literature DB >> 31719791 |
Moges Agazhe Assemie1, Cheru Tesema Leshargie2, Pammla Petrucka3,4.
Abstract
BACKGROUND: Loss to follow-up (LTFU) is a major public health problem to antiretroviral therapy (ART) programs in sub-Saharan Africa. Failure to account for patients' LTFU outcomes (self-transfers and restarts) can result in inaccurate reporting of retention in care. In Ethiopia, specifically in the Benishangule Gumuz region, high LTFU reported patients, who were not assessed for their outcomes, are identified as a gap. Therefore, our objective was to determine the outcomes (alive or dead) of patients lost to follow-up (LTFU) from ART and identify factors associated with successful tracing and mortality of these patients.Entities:
Keywords: ART tracing; Antiretroviral therapy; Cotrimoxazole preventive therapy; Ethiopia; Loss to follow-up; Mortality
Year: 2019 PMID: 31719791 PMCID: PMC6836319 DOI: 10.1186/s41182-019-0181-6
Source DB: PubMed Journal: Trop Med Health ISSN: 1348-8945
Socio-demographic characteristics of patients included in the study
| Variables | Numbers (%) |
|---|---|
| Sex of respondent | |
| Male | 150 (45.5) |
| Female | 180 (54.5) |
| Age | |
| 18–28 years | 119 (36.1) |
| 29–40 years | 136 (41.2) |
| > 40 years | 75 (23.7) |
| Marital status | |
| Never married | 72 (28.9) |
| Married | 98 (39.4) |
| Divorced | 56 (22.5) |
| Widowed | 23 (9.2) |
| Educational status | |
| No education | 89 (35.7) |
| Primary | 98 (39.3) |
| Secondary and above | 62 (25.0) |
| Occupation | |
| Government employee | 39 (15.7) |
| Daily laborer | 72 (28.9) |
| Farmer | 94 (37.7) |
| Self-employed | 44 (17.7) |
Baseline clinical and related characteristics of patients included in the study
| Variable | Number (%) |
|---|---|
| Functional status | |
| Working | 124 (37.6) |
| Ambulatory | 91 (28.6) |
| Bedridden | 115 (34.8) |
| CPT | |
| Received | 211 (64) |
| Not received | 119 (36) |
| Isoniazid preventive therapy (IPT) | |
| Not received IPT | 235 (71.21) |
| Received IPT | 95 (28.79) |
| Duration of follow-up on ART | |
| Follow-up time < 12 months | 222 (67) |
| Follow-up time > 12 months | 108 (33) |
| WHO clinical stage | |
| I | 35 (11) |
| II | 69 (21) |
| III | 140 (42) |
| IV | 86 (26) |
| Opportunistic infection | |
| Opportunistic infection | 131 (39.70) |
| No opportunistic infection | 199 (60.30) |
Factors associated with successful tracing of LTFU adult HIV-positive patients
| Variable | Tracing | Crude OR (95% CI) | Adjusted OR (95% CI) | ||
|---|---|---|---|---|---|
| Not traced | Traced | ||||
| Age | |||||
| 18–28 years | 27 (33.3) | 92 (37) | 1 | 1 | |
| 29–40 years | 35 (43.2) | 101 (41) | 0.84 (0.47,1.51) | 0.88 (0.49–1.60) | 0.674 |
| > 40 years | 19 (23.5) | 56 (22) | 0.86 (0.44,1.70) | 0.93 (0.46–1.87) | 0.842 |
| CPT | |||||
| Not received | 28 (34.6) | 91 (37) | 1.09 (0.64,1.84) | 0.89 (0.51–1.56) | 0.679 |
| Received | 53 (65.4) | 158 (63) | 1 | 1 | |
| Tracing methods | |||||
| Phone | 15 (18.5) | 95 (38) | 2.71 (1.47,5.03) | 2.97 (1.58–5.59) | 0.001* |
| Field/home visit | 66 (81.5) | 154 (62) | 1 | 1 | |
| Clinical stage | |||||
| I/II | 24 (29.6) | 80 (32) | 1 | 1 | |
| III | 33 (40.7) | 107 (43) | 0.97 (0.53,1.77) | 1.09 (0.59–2.02) | 0.793 |
| IV | 24 (29.6) | 62 (25) | 0.78 (0.40,5.26) | 0.72 (0.36–1.45) | 0.364 |
| Follow-up time | |||||
| < 12 months | 62 (76.5) | 160 (64) | 1 | 1 | |
| > 12 months | 19 (23.5) | 89 (36) | 1.82 (1.02,3.23) | 2.13 (1.17–3.88) | 0.013 |
*p value for statistically significant variable
Factors associated with mortality of adult HIV-positive patients LTFU
| Variable | Outcomes number (%) | Crude OR (95% CI) | Adjusted OR (95% CI) | ||
|---|---|---|---|---|---|
| Deceased | Alive | ||||
| Age category | |||||
| 18–28 years | 17 (29.8) | 75 (39.1) | 1 | 1 | |
| 29–40 years | 23 (40.4) | 78 (40.6) | 0.77 (0.38,1.55) | 0.78 (0.38–1.60) | 0.491 |
| > 40 years | 17 (29.8) | 39 (20.3) | 0.52 (0.24,1.13) | 0.54 (0.24–1.20) | 0.129 |
| CPT | |||||
| Not received | 11 (19.3) | 80 (41.7) | 2.98 (1.46,6.12) | 2.59 (1.22–5.59) | 0.013 |
| Received | 46 (80.7) | 112 (58.3) | 1 | 1 | 1 |
| Tracing methods | |||||
| Phone | 16 (28.1) | 79 (41.1) | 1.79 (0.94,3.42) | 1.53 (0.78–3.02) | 0.217 |
| Field work | 41 (71.9) | 113 (58.9) | 1 | 1 | 1 |
| Clinical stage | |||||
| I/II | 16 (28.1) | 64 (33.3) | 1 | 1 | |
| III | 22 (38.6) | 85 (44.3) | 0.97 (0.45,1.99) | 1.03 (0.49–2.17) | 0.932 |
| IV | 19 (33.3) | 43 (22.4) | 0.57 (0.26,1.22) | 0.69 (0.31–1.54) | 0.369 |
| Follow-up time | |||||
| < 12 months | 40 (70.2) | 120 (62.5) | 1 | 1 | |
| > 12 months | 17 (29.8) | 72 (37.5) | 1.41 (0.75,2.67) | 1.57 (0.77–2.94) | 0.231 |
*p value for statistically significant variable